|
Date: Feb 8, 2012
By:
Bill Gillette
| Source: Dermatology Times E-News
|
The American Board of Dermatology has warned residents that the practice of using so-called “airplane notes” to cheat on certification exams is illegal, the board’s executive director says.
Date: Feb 8, 2012
By:
Bill Gillette
| Source: Dermatology Times E-News
|
The tattoo boom of recent years has spawned an additional growth industry. The ranks of tattoo removal practitioners have increased substantially over the past five years, with revenue rising at an average annual rate of about 21 percent to $65.6 million in 2012, market analysis firm IBISWorld reports.
Date: Feb 8, 2012
By:
Bill Gillette
| Source: Dermatology Times E-News
|
A new study has identified key signals that regulate protective and sometimes pathological skin inflammation, and also identifies a “gatekeeper” that, when lost, can cause inflammatory skin disease in the absence of injury or infection.
Date: Feb 1, 2012
By:
Cheryl Guttman Krader
| Source: Dermatology Times
|
Even though botulinum toxin type A is one of the most potent neurotoxins known, its injection into muscles for the reduction of hyperfunctional lines is one of the safest procedures being performed in cosmetic dermatology. And the favorable risk-to-benefit profile of the toxin is fueling its use in an expanding number of off-label applications, says Thomas E. Rohrer, M.D.
Date: Feb 1, 2012
By:
Zoe Diana Draelos, M.D.
| Source: Dermatology Times
|
The p53 gene is very important in dermatology for the prevention of skin cancer. P53 is the gene that is activated when viable epidermal skin cells are damaged by UV radiation. UV radiation strikes the skin and is first transformed to heat by an organic sunscreen and possibly reflected by an inorganic sunscreen. If the sunscreen fails to diffuse all of the damaging UV radiation, keratinocytes function to reflect and scatter the radiation.
Date: Feb 1, 2012
By:
Lisette Hilton
| Source: Dermatology Times
|
New safety profile data continues to emerge on biologics used in psoriasis. Among the findings: Today's biologics do not appear to increase serious infection risk; the drugs' short-term cancer risk profile is promising; but concerns remain about long-term cancer risk with all biologics and cardiovascular risk with interleukin-12/23, ustekinumab (Stelara, Janssen Biotech).
Date: Feb 1, 2012
By:
Bill Gillette
| Source: Dermatology Times E-News
|
The Food and Drug Administration has approved Picato gel (ingenol mebutate, Leo Pharma) as a treatment for actinic keratoses on the face, scalp, trunk and extremities.
Date: Feb 1, 2012
By:
Cheryl Guttman Krader
| Source: Dermatology Times
|
A naturally secreted, embryonic-like human cell conditioned media (hCCM) used as a follicle holding solution (FHS) holds promise for improving outcomes of hair transplantation surgery, according to clinical trial findings reported by Neil S. Sadick, M.D., at the 2011 annual meeting of the American Society for Dermatologic Surgery.
Date: Feb 1, 2012
By:
Karen Nash
| Source: Dermatology Times
|
Beginning in 2003, with approval of human collagen and in the following years the introduction of products containing hyaluronic acid, calcium hydroxylapatite, poly-L-lactic acid and more, it's no surprise that fillers have taken on an ever-increasing role in aesthetic dermatology. On Call wondered whether dermatologists' treatment techniques have changed as a result of the growing array of product options, and if so, how.
|
| 
Practice Tools
